BR0212047A - Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável - Google Patents

Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável

Info

Publication number
BR0212047A
BR0212047A BR0212047-0A BR0212047A BR0212047A BR 0212047 A BR0212047 A BR 0212047A BR 0212047 A BR0212047 A BR 0212047A BR 0212047 A BR0212047 A BR 0212047A
Authority
BR
Brazil
Prior art keywords
nucleic acid
composition
immunogen
vector
analogs
Prior art date
Application number
BR0212047-0A
Other languages
English (en)
Inventor
Peter Birk Rasmussen
Martin Roland Jensen
Klaus Gregorius Nielsen
Peter Koefoed
Florence Dal Degan
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32870659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0212047(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of BR0212047A publication Critical patent/BR0212047A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

"USO DE UM IMUNOGENE POLIAMINOáCIDO OU CONJUGADO, COMPOSIçãO IMUNOGêNICA, FRAGMENTO DE áCIDO NUCLEICO, VETOR, CéLULA TRANSFORMADA, COMPOSIçãO PARA INDUZIR A PRODUçãO DE ANTICORPOS CONTRA AMILóIDE, E, LINHAGEM DE CéLULA ESTáVEL". São divulgados novos usos para combater doenças caracterizadas pela deposição de amilóide. Os usos no geral contam com a imunização contra a proteína precursora de amilóide (APP) ou beta amilóide (A<225>). A imunização é preferivelmente efetuada pela administração de análogos de APP ou A<225> autólogos, os ditos análogos sendo capazes de induzir a produção de anticorpo contra os polipeptídeos amiloidogênicos autólogos. Especialmente preferido como um imunogene é o A<225> autólogo que foi modificada pela introdução de um único ou uns poucos epítopos de célula T estranhos, imunodominantes e promíscuos. Também são divulgadas a vacinação de ácido nucleico contra APP ou A<225> e a vacinação usando vacinas vivas assim como usos e meios úteis para a vacinação. Tais usos e meios incluem usos para a preparação de análogos e formulações farmacêuticas, assim como fragmentos de ácido nucleico, vetores, células transformadas, polipeptídeos e formulações farmacêuticas.
BR0212047-0A 2001-08-20 2002-08-20 Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável BR0212047A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101231 2001-08-20
DKPA200200558 2002-04-16
PCT/DK2002/000547 WO2003015812A2 (en) 2001-08-20 2002-08-20 Beta-amyloid-analogue-t-cell epitop vaccine

Publications (1)

Publication Number Publication Date
BR0212047A true BR0212047A (pt) 2004-08-17

Family

ID=32870659

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212047-0A BR0212047A (pt) 2001-08-20 2002-08-20 Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável

Country Status (30)

Country Link
US (3) US20030157117A1 (pt)
EP (3) EP1420815B2 (pt)
JP (2) JP2004538332A (pt)
KR (3) KR20100086520A (pt)
CN (1) CN101675992B (pt)
AR (1) AR036270A1 (pt)
AT (1) ATE334698T1 (pt)
AU (3) AU2002325199B2 (pt)
BR (1) BR0212047A (pt)
CA (1) CA2457140C (pt)
CO (1) CO5560581A2 (pt)
CY (1) CY1105737T1 (pt)
DE (1) DE60213615T3 (pt)
DK (1) DK1420815T3 (pt)
EA (2) EA011610B1 (pt)
ES (1) ES2269749T5 (pt)
HK (1) HK1064934A1 (pt)
HR (2) HRP20040218A2 (pt)
HU (1) HUP0400669A3 (pt)
IL (2) IL159964A0 (pt)
IS (1) IS7133A (pt)
ME (1) MEP43208A (pt)
MX (1) MXPA04001467A (pt)
MY (1) MY144532A (pt)
NZ (2) NZ547224A (pt)
PL (1) PL215125B1 (pt)
PT (1) PT1420815E (pt)
RS (1) RS51699B (pt)
SI (1) SI1420815T1 (pt)
WO (1) WO2003015812A2 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02007796A (es) 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
BR0108566A (pt) * 2000-02-21 2002-11-19 Pharmexa As Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
KR100546066B1 (ko) * 2003-03-21 2006-01-26 한국생명공학연구원 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
EP1687333A2 (en) * 2003-10-30 2006-08-09 Pharmexa A/S Method for down-regulation of vegf
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
KR100639397B1 (ko) 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
NZ562434A (en) * 2005-05-05 2010-04-30 Merck & Co Inc Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101434935B1 (ko) 2005-11-30 2014-10-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
KR20080103560A (ko) * 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2118300T3 (pl) * 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008106657A2 (en) * 2007-03-01 2008-09-04 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
WO2008124646A2 (en) * 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
JP5349297B2 (ja) 2007-04-20 2013-11-20 一般財団法人化学及血清療法研究所 ペプチド免疫応答増強方法
JP2011527681A (ja) * 2008-07-08 2011-11-04 メルク・シャープ・エンド・ドーム・コーポレイション アルツハイマー病治療用ワクチン
KR101640147B1 (ko) * 2008-10-16 2016-07-18 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 변성된 아밀로이드 베타 펩티드
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
KR101854943B1 (ko) 2010-10-26 2018-05-04 에이씨 이뮨 에스.에이. 소수성 부분을 통해 변형된 펩티드를 포함하는 리포솜 기반 구조체
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP2887955B1 (en) * 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
WO2015036646A1 (es) * 2013-09-13 2015-03-19 Fundación Pública Andaluza Progreso Y Salud Combinaciones de proteínas agregantes y chaperonas moleculares para el tratamiento de proteinopatías o enfermedades conformacionales
CN106103467B (zh) * 2014-03-11 2019-12-31 艾克斯-马赛大学 与细胞膜神经节苷脂相互作用的嵌合肽
JP2018508481A (ja) * 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN104880441B (zh) * 2015-05-14 2017-12-22 上海皓拓生物技术有限公司 β‑分泌酶特异性抑制剂的筛选方法及其筛选系统
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10912773B2 (en) 2016-10-28 2021-02-09 H. Lundbeck A/S Combinations comprising substituted imidazo[1,5-a]pyrazinones as PDE1 inhibitors
CN109803658A (zh) 2016-10-28 2019-05-24 H.隆德贝克有限公司 包含用于治疗精神疾病和/或认知障碍的咪唑并吡嗪酮的组合治疗
EP3568411B1 (en) * 2017-01-13 2024-03-06 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
CN108175855B (zh) * 2017-05-25 2020-05-01 成都安特金生物技术有限公司 一种狂犬病免疫原性结合物
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
SG11202005361RA (en) 2017-12-14 2020-07-29 H Lundbeck As Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US10828351B2 (en) * 2018-04-10 2020-11-10 Ac Immune Sa Anti-abeta therapeutic vaccines
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
WO2020226854A2 (en) * 2019-04-12 2020-11-12 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
GB202008250D0 (en) * 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5192688A (en) 1988-08-15 1993-03-09 Switzer Iii Robert C Histological analysis method
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5200339A (en) 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
EP0633942A1 (en) 1992-03-27 1995-01-18 Whitehead Institute For Biomedical Research Non-infectious hiv particles and uses therefor
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
DK100592D0 (da) 1992-08-10 1992-08-10 Mouritsen & Elsner Aps Metode til kemisk kobling paa faste faser
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DK0735893T3 (da) * 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
IL115743A0 (en) 1994-10-28 1996-01-19 American Nat Red Cross A mammal with cells containing a transgene and its production
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
WO1996040718A1 (en) 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Expression of lipoproteins
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5985581A (en) 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
JP2001509178A (ja) 1997-01-22 2001-07-10 ザイコス インク． 核酸を輸送するための微粒子
WO1999024468A1 (en) 1997-11-11 1999-05-20 The Board Of Regents Of The University Of Oklahoma An alzheimer-related, endothelium-derived toxic factor and methods for its use
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CA2338269A1 (en) 1998-07-21 2000-02-03 M & E Biotech A/S Coating of solid surfaces with activated polyhydroxypolymers
JP2002525060A (ja) 1998-09-15 2002-08-13 ファーメクサ エイ／エス オステオプロテゲリンリガンド活性をダウンレギュレートする方法
NZ511055A (en) 1998-10-05 2003-10-31 Pharmexa As Novel methods for therapeutic vaccination
WO2000027944A1 (en) † 1998-11-06 2000-05-18 Baker Hughes Incorporated Drilling fluid systems with improved fluid loss properties
WO2000040741A2 (en) 1999-01-07 2000-07-13 The Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services, The National Institutes Of Health Lentivirus vector system
ES2228497T3 (es) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. Composicion adyuvante que comprende saponina y un oligonucleotido inmunoestimulante.
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
PE20010212A1 (es) 1999-06-01 2001-02-22 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
MXPA02005576A (es) 1999-11-29 2002-12-13 Neurochem Inc Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
CN101935352A (zh) * 1999-12-08 2011-01-05 智力神经系统学公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
MXPA02007796A (es) 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
BR0108566A (pt) 2000-02-21 2002-11-19 Pharmexa As Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
GB0004530D0 (en) 2000-02-25 2000-04-19 Univ Nottingham Adjuvants
PT1284998E (pt) * 2000-05-22 2005-06-30 Univ New York Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
SK5482003A3 (en) 2000-11-10 2004-03-02 Wyeth Corp Adjuvant combination formulations
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
JP2002273199A (ja) * 2001-03-15 2002-09-24 Idemitsu Petrochem Co Ltd ガス状流体の抜き出し方法
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030185845A1 (en) 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins
EP1467751A2 (en) 2002-01-17 2004-10-20 Pharmexa A/S Immunogenic cea
WO2003075951A2 (en) 2002-03-11 2003-09-18 Pharmexa A/S Novel application of vaccination against tnf-alpha
CA2493119A1 (en) 2002-07-17 2004-01-22 Mindset Biopharmaceuticals Usa Inc. Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease

Also Published As

Publication number Publication date
EP1420815A2 (en) 2004-05-26
ES2269749T3 (es) 2007-04-01
YU13304A (sh) 2006-08-17
KR101057488B1 (ko) 2011-08-19
WO2003015812A3 (en) 2004-03-25
AU2010212381A1 (en) 2010-09-09
MY144532A (en) 2011-09-30
AU2010212381B2 (en) 2012-01-19
SI1420815T1 (sl) 2006-12-31
HRP20120283A2 (hr) 2012-06-30
HRP20040218A2 (en) 2004-08-31
IL188506A (en) 2017-08-31
NZ547224A (en) 2008-06-30
CA2457140A1 (en) 2004-02-27
US8871212B2 (en) 2014-10-28
DE60213615D1 (de) 2006-09-14
DE60213615T3 (de) 2017-11-23
PL215125B1 (pl) 2013-10-31
CO5560581A2 (es) 2005-09-30
CY1105737T1 (el) 2010-12-22
US20100047262A1 (en) 2010-02-25
KR20040044465A (ko) 2004-05-28
JP2004538332A (ja) 2004-12-24
ES2269749T5 (es) 2017-12-04
US20030157117A1 (en) 2003-08-21
DK1420815T3 (da) 2006-12-04
JP5114455B2 (ja) 2013-01-09
WO2003015812A2 (en) 2003-02-27
EP1420815B2 (en) 2017-08-09
EA007533B1 (ru) 2006-10-27
EA200600974A1 (ru) 2006-10-27
MXPA04001467A (es) 2005-02-17
PL369099A1 (en) 2005-04-18
EA200400332A1 (ru) 2004-08-26
NZ530940A (en) 2007-11-30
CA2457140C (en) 2014-08-05
HK1064934A1 (en) 2005-02-08
CN101675992A (zh) 2010-03-24
EP3299029A1 (en) 2018-03-28
EA011610B1 (ru) 2009-04-28
AR036270A1 (es) 2004-08-25
CN101675992B (zh) 2014-05-21
HUP0400669A3 (en) 2011-07-28
ATE334698T1 (de) 2006-08-15
KR20090074830A (ko) 2009-07-07
PT1420815E (pt) 2006-12-29
MEP43208A (en) 2011-02-10
HUP0400669A2 (hu) 2005-01-28
EP1420815B1 (en) 2006-08-02
IL159964A0 (en) 2004-06-20
AU2002325199B2 (en) 2007-09-20
IS7133A (is) 2004-01-29
RS51699B (sr) 2011-10-31
AU2007249087A1 (en) 2008-01-10
JP2009280582A (ja) 2009-12-03
KR20100086520A (ko) 2010-07-30
IL188506A0 (en) 2008-04-13
AU2007249087B2 (en) 2010-05-20
DE60213615T2 (de) 2007-08-09
US20050163744A1 (en) 2005-07-28
EP1685847A1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
BR0212047A (pt) Uso de imunogene, poliaminoácido ou conjugado, composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra amilóide, e, linhagem de célula estável
BR0108566A (pt) Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
ES2272012T3 (es) Proteinas de fusion que comprenden proteinas tat y/o nef de vih-1.
JP5566684B2 (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
Vinner et al. Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons
RU2211050C2 (ru) Вакцины с адъювантом ltb
US20060153862A1 (en) Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses
WO2001005820A3 (en) Method for down-regulating gdf-8 activity
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
BR112014029861B1 (pt) Compostos imunogênicos, composição e uso de composto
UA126852C2 (uk) Лікування атопічного дерматиту собак
NO20051779L (no) Immunisering mot autologt ghrelin
US9534020B2 (en) Immunogenic polypeptides comprising a modified loop peptide presenting the HIV-1 GP120 3074 mAb epitope and scaffold proteins containing said peptide
JP2022525768A (ja) サポニン系ワクチンアジュバント
KR20060118630A (ko) 나이제리아 고노리아 또는 나이제리아 메닌지티디스에 대한재조합 필린을 함유한 백신
JP5913406B2 (ja) 変異型大腸菌易熱性エンテロトキシン
KR100815888B1 (ko) Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신
US11672852B2 (en) Universal mammalian influenza vaccine
KR20180133678A (ko) 신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
RU2827202C1 (ru) Рекомбинантная плазмидная ДНК pVL3-HA/H5, несущая ген гемагглютинина вируса гриппа A (H5N8), рекомбинантный штамм клеточной линии яичника китайского хомячка CHO-K1-H5 и рекомбинантный гемагглютинин вируса гриппа A (H5N8), продуцируемый штаммом CHO-K1-H5 и предназначенный для создания профилактических препаратов и серологической диагностики вируса гриппа A H5N8
RU2781057C2 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
RU2781057C9 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
WO2022055375A1 (es) Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante
Ben-Yedidia A peptide-based vaccine against influenza
YU87201A (sh) Postupak za nishodnu regulaciju gdf-8 aktivnosti

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: PHARMEXA A/S (DK)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090029383/RJ DE 26/03/2009.

B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S (DK)

Free format text: TRANSFERIDO DE: PHARMEXA A/S

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.